2026 AbbVie Golden Ticket Winner

AbbVie and MBC BioLabs are delighted to announce ResNovas Therapeutics as the winner of the 2026 AbbVie Golden Ticket. The ResNovas Therapeutics team was selected from a competitive applicant pool for their potential to generate transformational therapies.

ResNovas will receive sponsored access to an MBC BioLabs laboratory facility and access to our core lab filled with cutting-edge technology to advance their research and development. They will also receive mentoring and guidance from AbbVie’s world-class team of scientists and pharmaceutical business leaders.

Congratulations to the ResNovas Therapeutics team!

About ResNovas Therapeutics

ResNovas is a preclinical-stage biotech developing novel therapeutic approaches for highly validated but historically undruggable targets in oncology and beyond. The company has been selected and supported by leading programs, including the AIM-HI Accelerator Fund; the MBC Platinum Program, sponsored by Eli Lilly and Ono Venture Investment; the MBC Golden Ticket, sponsored by Ono Venture Investment; StartX; Microsoft for Startups; and NVIDIA Inception. Early supporters include Dalena Capital, Rebel Capital Canada, seasoned biotech executives, serial angel investors, and Astellas Venture Management.

About MBC BioLabs

At MBC BioLabs, we believe that startups are the greatest force for positive change in the world. We are dedicated to helping biotech startups succeed – we like to say that we enable awesome. We offer flexible and cost-effective lab space, complete with operational support and millions of dollars’ worth of state-of-the-art equipment and instrumentation, along with a vibrant community of like-minded individuals tackling the world’s biggest problems. For more information, visit www.mbcbiolabs.com.